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ABSTRACT The efficient export of a subset ofEscherichia
coli envelope proteins is dependent upon the product of the secB
gene. Previous studies indicated that SecB promotes the export
of the periplasmic maltose-binding protein (MBP) by prevent-
ing premature folding of the precursor MBP in the cytoplasm
into an export-incompetent form. In this study, SecB has been
purified to homogeneity and shown to be a soluble, cytoplas-
mic, multimeric protein composed of identical 17-kDa sub-
units. SecB was required for efficient in vitro translocation of
MBP into inverted membrane vesicles. The addition of purified
SecB to an in vitro system prepared from SecB- cells signifi-
cantly enhanced MBP translocation. The purified protein also
quantitatively retarded folding of precursor MBP into a stable,
protease-resistant conformation in the absence of membranes.
Finally, the inclusion of excess purified SecB in a SecB+ in vitro
system significantly prolonged the time in which precursor
MBP remained competent for posttranslational import into
membrane vesicles.
A number of components of the protein export machinery of
Escherichia coli have been identified by genetic approaches
[reviewed by Oliver (1)] and by biochemical approaches using
in vitro protein translocating systems (2-4). The export of a
subset of envelope proteins, including the periplasmic mal-
tose-binding protein (MBP), is adversely affected by muta-
tions in secB, a nonessential gene that maps near min 81 on
the E. coli chromosome (5, 6). We have presented (7) evi-
dence that the SecB protein functions as an antifolding factor
that specifically interacts with the mature region of the
precursor MBP (pre-MBP) to prevent its premature folding in
the cytoplasm into a translocation-incompetent form. Kuma-
moto and Gannon (8) reached a similar conclusion by using a
different experimental approach. Thus a specific biochemical
function was assigned to the product of an E. coli sec gene,
which complemented earlier work by Randall and Hardy (9)
correlating the folding of pre-MBP into its stable tertiary
structure in the cytoplasm with the loss ofexport competence.
The essential role of protein conformation during membrane
translocation has been recognized in eukaryotic cells as well
(10). For example, unfolding factors that facilitate transloca-
tion of proteins into the endoplasmic reticulum and mitochon-
dria have been described (11, 12).
An understanding ofprotein export in E. coli will be greatly
aided by the purification and characterization of the individ-
ual components that mediate this process and eventual
reconstitution of a complete protein translocating system in
vitro. This study was undertaken to demonstrate the SecB
dependence of MBP translocation in vitro and to purify
biologically active SecB capable of interacting with newly
synthesized pre-MBP to retard its folding and promote its
import into membrane vesicles.
MATERIALS AND METHODS
In Vitro MBP Synthesis and Translocation. MBP was
synthesized in vitro by using a coupled E. coli transcription-
translation system, in the presence or absence of membrane
vesicles, and plasmid templates in which the wild-type malE
or malEAJ16 alleles were under transcriptional control of the
lacUV5 promoter-operator, as described (7, 13). Cells of
strain MC4100 (14) and CK1953 [MC4100 secB::TnS (6)] used
for the preparation of reaction components (S-30, S-100,
membrane-free ribosomes, and inside-out cytoplasmic mem-
brane vesicles) were grown at 30'C to an OD600 of 1.0 in TB
medium (pH 7.8) containing 0.2% glucose. To assess trans-
location, half of each sample was treated with proteinase K
(55 Ag/ml). All of the samples were solubilized by boiling in
1% NaDodSO4, and then the MBP species were immunopre-
cipitated and analyzed by NaDodSO4/PAGE in 10% poly-
acrylamide gels and autoradiography (15). The amount of
radioactivity present as pre-MBP and mature MBP was
quantitated as described (7).
Plasmid Constructions. Plasmid pJW21 was constructed by
ligation of the 1.52-kilobase Pvu II-HindIII fragment of
plasmid pDC2 [containing the secB+ gene (6, 16)] with the
large Pvu II-HindlIl fragment of vector pZ152 (17), after
fragment isolation by low-melting-temperature agarose gel
electrophoresis. Plasmid pJW25 (containing the secB+ gene
under transcriptional control of the T7 RNA polymerase) was
constructed by inserting the same 1.52-kilobase fragment of
pDC2 into the Stu I site of vector pET-7 (18). The direction
of secB transcription by T7 RNA polymerase was from the
HindIII site toward the Pvu II site.
Purification of SecB. Cells of strain BL21(DE3) containing
the cloned gene for the T7 RNA polymerase under control of
the inducible lacUVS promoter (19) and plasmid pJW25 were
grown at 30'C to an OD6w of 1.5 in LB medium (pH 7.8) and
then induced with 1 mM isopropyl thiogalactoside for 2 hr.
The cell pellet (4.4 g) was washed once, and then suspended
in 20 ml of lysis buffer [20 mM Tris'HCI (pH 7.4) containing
2 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, and
lysozyme at 100 ,ug/ml]. The cells were incubated at 00C for
10 min, then MgSO4 (5 mM) and DNase I (10 ttg/ml) were
added, and, after 10 min of further incubation, the mixture
was centrifuged at 30,000 x g for 15 min. The pellet was
resuspended in lysis buffer and the process was repeated.
The supernatant fluids were combined, dialyzed overnight
against 20 mM Tris HCl (pH 7.4) containing 0.1 mM phenyl-
Abbreviations: MBP, maltose-binding protein; pre-MBP, precursor
MBP.
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methylsulfonyl fluoride, and centrifuged at 30,000 x g for 20
min. The soluble extract was applied to a 1.5 x 10 cm column
of Q-Sepharose (Pharmacia), equilibrated with the same
buffer, washed with 30 ml of buffer, and the proteins were
eluted with a NaCl gradient of 0-500 mM (total volume, 300
ml). Fractions were assayed by NaDodSO4/PAGE; the
SecB-containing fractions (eluted at 0.3 M NaCl) were
pooled, precipitated with 80% (wt/vol) ammonium sulfate,
and dialyzed overnight against 50 mM potassium phosphate
(pH 7.4) containing 150 mM NaCl and 0.1 mM phenylmethyl-
sulfonyl fluoride. The dialyzed extract was concentrated to 2
ml with Centricon concentrators (Amicon; molecular weight
cut-off, 10,000) and chromatographed on a 1.5 x 100 cm
S-200 HR (Pharmacia) gel filtration column. The peak tubes
of SecB-containing fractions were pooled, concentrated with
the Centricon concentrators, and rechromatographed on the
same S-200 HR column.
Protein concentration was determined by the method of
Lowry et al. (20) with bovine serum albumin as a standard.
Quantitation of purity was determined by use of a LKB laser
scanner after staining and destaining NaDodSO4/PAGE gels.
Isoelectric focusing was performed as described (21) utilizing
Pharmalyte pH 2.5-5.0 ampholytes (Pharmacia).
In Vivo Radiolabeling ofCellular Proteins. Cells were grown
in glycerol minimal medium to midlogarithmic phase and
radiolabeled with [35S]methionine for 10 min, as described by
Rasmussen et al. (13). Incorporation of label was terminated
by precipitation with trichloroacetic acid. SecB was immu-
noprecipitated from detergent-solubilized cell extracts and
analyzed by NaDodSO4/PAGE and autoradiography. Anti-
SecB rabbit IgG was affinity-purified using SecB coupled to
Sepharose CL-4B beads (Pharmacia), after DEAE-cellulose
column chromatography.
In Vitro Assay ofMBP Folding. MBP was synthesized in the
absence of membranes, and at each time point an aliquot was
removed and quickly diluted into ice-cold 40 mM triethanol-
amine acetate (pH 7.8) containing 0.5% methionine. Half of
each sample was immediately treated with proteinase K (55
,ug/ml), and the MBP species were immunoprecipitated and
analyzed by NaDodSO4/PAGE as described above. The
percent of precursor that was sensitive to proteolysis was
calculated as described by Randall and Hardy (9).
RESULTS
SecB Is Required for Maxmal MBP Translocation into
Membrane Vesicles in Vitro. Pre-MBP synthesized in vitro in
an E. coli transcription-translation system in the presence of
inside-out cytoplasmic membrane vesicles can be imported
into vesicles and converted to mature MBP. The use of a
protease-sensitive MBP species designated MBPA116 per-
mits import into vesicles to be quantitatively monitored by
determining the fraction of total MBP synthesized that is
resistant to proteinase K digestion (J.B.W., C. H. MacGreg-
or, D. N. Collier, J. D. Fikes, P.H.R., and P.J.B., Jr.,
unpublished data). [The in vivo export kinetics of MBPA116
are identical to those of wild-type MBP. Although MBPA116
export is somewhat less SecB-dependent than wild-type
MBP, its export is clearly much more efficient in SecB+ cells
compared to SecB- cells (7).] When MBPA116 was synthe-
sized by using an S-30 fraction prepared from SecB- cells,
translocation was greatly reduced (9%o protected from pro-
tease digestion) compared to that obtained with an S-30
fraction from SecB+ cells (48% protected) (Fig. 1). S-100
fractions from either SecB+ or SecB- cells supplemented
with purified wild-type ribosomes promoted normal levels of
MBPA116 synthesis; virtually all of which remained unpro-
cessed and unprotected from protease digestion in the ab-
sence of added membrane vesicles. Vesicles prepared from
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FIG. 1. SecB requirement for in vitro MBP translocation.
MBPA116 was synthesized in vitro in the presence of[P5S]methionine
by using an S-30 fraction, an S-100 fraction plus added wild-type
ribosomes, or an S-100 fraction plus added ribosomes and vesicles
(MB). Fractions were prepared from wild-type SecB1 cells (strain
MC4100; designated B+) and SecB- cells [strain CK1953
(secB::TnS); designated B-]. After the reaction mixtures were
incubated for 15 min, halfof each sample was treated with proteinase
K. Subsequently, MBPA116 was immunoprecipitated and analyzed
by NaDodSO4/PAGE and autoradiography. The lanes containing the
protease-treated samples were exposed to film twice as long as
untreated samples. The positions of precursor (p) and mature (m)
MBPA116 are indicated by arrows. The percentage oftotal MBPA116
synthesized that was protected from protease digestion (% prot) (i.e.,
translocated into vesicles) was calculated after measuring the amount
of radioactivity present as pre-MBP and mature MBP before (-K)
and after (+K) proteinase K treatment. Note that a small amount of
MBPA116 was matured and protease-resistant when the SecB+ S-100
was employed without added vesicles, indicating that not all the
membranes were removed when this fraction was prepared.
activity when added to a SecB+ S-100 fraction, yet little
translocation occurred when the SecB- membrane vesicles
were added to a SecB- S-100 fraction (18% versus 71%
translocated when SecB + S-100 and membranes were
employed). The combination ofwild-type membrane vesicles
and the SecB- S-100 fraction also resulted in an intermediate
level of MBPA116 translocation activity equal to that of
SecB- vesicles used with a SecB+ S-100 fraction (Fig. 1).
From the above results, it was apparent that SecB was
required for efficient in vitro translocation of MBP into
membrane vesicles. Previous in vivo studies have revealed
that efficient export of only a subset of E. coli envelope
proteins is SecB-dependent (5-7). Our in vitro analysis was
consistent with those observations. In addition to MBP,
translocation of the SecB-dependent oligopeptide-binding
protein also was found to be deficient when SecB- fractions
were employed, whereas in vitro translocation of the SecB-
independent ribose-binding protein was unaffected by SecB
availability (data not shown).
Purification of SecB. SecB was purified from cells contain-
ing the secB+ gene on the multicopy plasmid pJW25 under the
transcriptional control of the T7 RNA polymerase. After a
2-hr induction of the T7 RNA polymerase by isopropyl
thiogalactoside, a major protein band of =17 kDa, represent-
ing 30% of the total soluble protein, was easily recognized by
NaDodSO4/PAGE. SecB was purified from the crude soluble
fraction. An analysis of the purification procedure by
NaDodSO4/PAGE is shown in Fig. 2. The total quantity of
protein obtained was 42 mg, representing an overall purifi-
cation of >3-fold with a 50% yield. The purified protein had
a pI value of 3.95-4.1, as determined by isoelectric focusing.
The molecular mass of native SecB determined by gel
filtration chromatography (Sephadex G-200, Sephacryl S-200
HR, and Superose-12) was estimated to be 115 kDa and by
Ferguson analysis (22) on non-NaDodSO4 gels was estimated
to be 79 kDa (data not shown). Attempts to determine the
amino-terminal sequence were unsuccessful, indicating that
this terminus was blocked.
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FIG. 2. Purification of SecB. Aliquots from the steps of purifi-
cation were analyzed on a 12% NaDodSO4/polyacrylamide gel
stained with Coomassie blue. The samples applied to each lane
contained approximately equivalent amounts of SecB. Lanes: 1,
molecular mass standards (in kDa; phosphorylase b, albumin,
ovalbunmin, carbonic anhydrase, trypsin inhibitor, and a-
lactalbumin); 2, soluble cell extract; 3, dialyzed cell extract; 4,
Q-Sepharose pool; 5, first S-200 HR pool; and 6, second S-200 HR
pool. The percentage of SecB (% SecB) in each lane was determined
by scanning the gel.
The SecB Protein Is Absent from secB::Tn5 Mutant Cells.
To confirm the identity of purified SecB, rabbit antiserum
was prepared against the native protein. Affinity-purified IgG
antibodies precipitated a single 17-kDa protein from deter-
gent-solubilized [35S]methionine-radiolabeled SecB+ cells
(Fig. 3). This polypeptide was not present in extracts pre-
pared from cells of a secB: :TnS mutant and was precipitated
in large amounts from extracts of cells having the secB+ gene
on a multicopy plasmid under transcriptional control of either
E. coli RNA polymerase (pJW21) or T7 RNA polymerase
(pJW25).
Purified SecB Promotes in Vitro Translocation ofMBPA116.
The addition of purified SecB protein to a SecB- S-30
fraction significantly elevated the in vitro translocation of
MBPA116 into membrane vesicles (Fig. 4). Although as little
as 0.01 jig of SecB protein added to the reaction mixture
appeared to stimulate translocation, 0.1 jg clearly resulted in
a significant increase in the amount of MBPA116 imported
into vesicles. Translocation activity reached a maximum
3-fold increase with 1 ,tg ofadded SecB. It also appeared that
SecB had a somewhat stimulatory effect on the amount of
pre-MBP synthesized in vitro; however, this increase by itself
could not account for the increase in translocation efficiency
(J.B.W., unpublished data). The addition of purified SecB to
a SecB+ S-30 fraction did not significantly increase translo-
cation efficiency (data not shown).
SecB Availability Affects in Vitro Folding of pre-MBP.
Folding ofnewly synthesized wild-type pre-MBP into a stable
native tertiary structure can be monitored by the acquisition
of resistance to proteinase K digestion (7-9). The folding of
pre-MBP in the cytoplasm has been correlated with a loss in
the ability of this protein to be translocated across the
cytoplasmic membrane (9). We have demonstrated (7) that
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FIG. 3. Radioimmunoprecipitation of SecB. Midlogarithmic-
phase cells growing in glycerol minimal medium were radiolabeled
with [35S]methionine for 10 min and solubilized, and SecB was
immunoprecipitated and analyzed by NaDodSO4/PAGE and auto-
radiography. Lanes: 1, strain CK1953 (secB::TnS); 2, strain MC4100
(haploid secBP); 3, strain MC4100 pJW21; 4, strain BL21(DE3)
pJW25, uninduced; and 5, strain BL21(DE3) pJW25 induced for 2 hr
with 2 mM isopropyl thiogalactoside.
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FIG. 4. Stimulation of in vitro MBP translocation by purified
SecB. MBPA116 was synthesized by using a SecB' S-30 fraction in
the presence of various concentrations of purified SecB (10 ,ug of
bovine serum albumin was used as a control in the reaction mixture
without added SecB). After 15 min of incubation, half of each sample
was treated with proteinase K. Subsequently, MBPA116 was immu-
noprecipitated and analyzed by NaDodSO4/PAGE and autoradi-
ography. The lanes containing the protease-treated samples (+K)
were exposed to film for a 5-fold longer period of time than untreated
samples (-K). The percentage of total MBPA116 synthesized (%
prot) that was protected from proteinase K digestion was calculated
as described in Fig. 1.
the rate of folding of wild-type pre-MBP synthesized in vitro
in the absence of membranes was found to be accelerated
when a SecB- S-100 fraction was used and was greatly
retarded when the S-100 fraction was prepared from cells
harboring the secB+ gene on a multicopy plasmid. The
antifolding activity of purified SecB was investigated in this
study. At intervals after the initiation of pre-MBP synthesis,
aliquots were removed from the reaction and half of each
sample was treated with proteinase K. If pre-MBP had
completely folded, proteinase K digestion generated mature
MBP; whereas if pre-MBP had not completely folded, a
sufficient number ofresidues were accessible to the protease,
and no polypeptides were recovered by immunoprecip-
itation.
When pre-MBP was synthesized using a SecB- S-100















FIG. 5. Folding of pre-MBP synthesized in vitro is retarded by
purified SecB. The kinetics of folding of pre-MBP was monitored by
the loss of sensitivity to proteolytic degradation. Wild-type pre-MBP
was synthesized by using a SecB- S-100 fraction plus added SecB-
ribosomes, in the presence of various concentrations of purified
SecB or 2 Ag of bovine serum albumin (open circles) as control.
Samples were removed from the reaction mixtures at the indicated
times, and half 'of each sample was immediately treated with
proteinase K. Subsequently, the MBP was immunoprecipitated and
analyzed by NaDodSO4/PAGE and autoradiography. Resistance to
proteolysis was indicated by the conversion of pre-MBP to a form
that migrates identically to mature MBP. The percentage of the
pre-MBP synthesized that was sensitive to proteolytic degradation at
each time point was calculated. Note that pre-MBP is continuously
synthesized throughout the reaction period. Thus, even in the
absence of SecB, 100% of pre-MBP would not be expected to attain
a protease-resistant conformation during the time course of this
experiment.
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age of pre-MBP that retained a protease-sensitive conforma-
tion (Fig. 5). When purified SecB was included in the reaction
mixture, pre-MBP folding was reduced in a dose-dependent
manner. In fact, when 2 ,ug of SecB was included, folding of
the pre-MBP into a proteinase-resistant conformation was
virtually undetectable for as long as 16 min after initiating
pre-MBP synthesis. Folding of ribose-binding protein also
can be monitored by an identical assay (23). We found the
addition of SecB to have no measurable effect on the
acquisition of proteinase K resistance when this protein was
synthesized in vitro (data not shown).
Excess SecB Prolongs pre-MBP Competence for Posttrans-
lational Translocation. Posttranslational translocation can be
studied independently from cotranslational translocation in
an in vitro system by the addition of membranes to the
reaction mixture only subsequent to the termination of
protein synthesis. The effects of the inclusion of excess
purified SecB on the capacity of pre-MBP to remain compe-
tent for posttranslational translocation during continued
incubation at 37TC were investigated. Wild-type pre-MBP
was synthesized in the absence of membrane vesicles using
a SecB+ S-100 fraction. After 8 min, protein synthesis was
terminated by the addition of ribonuclease, and then vesicles
were added to individual aliquots of the reaction mixture at
intervals to 30 min, and in each case incubation was contin-
ued for another 15 min. Since wild-type pre-MBP was
synthesized in this experiment, translocation into vesicles
was monitored by determining the amount of pre-MBP that
was processed to mature MBP.
As shown in Fig. 6, wild-type pre-MBP rapidly became
incompetent for posttranslational import into vesicles. Trans-
location was undetectable if protein synthesis was terminated
20 min prior to the addition of vesicles. In marked contrast,
when 2 ,ug of purified SecB was included in the reaction
mixture, the proportion ofpre-MBP competent for posttrans-
lational import immediately after the termination of protein
synthesis was significantly increased. Furthermore, although
translocation activity did diminish somewhat at later time
points, the time period that pre-MBP remained translocation-
competent was markedly extended, such that import into
vesicles was easily detectable when vesicles were added 30











FIG. 6. Effect of purified SecB on posttranslational MBP trans-
location. Wild-type pre-MBP was synthesized by using a SecB+
S-100 fraction plus added SecB+ ribosomes, and 2 ug of purified
SecB (closed circles) or bovine serum albumin (open circles). After
8 min, protein synthesis was terminated and, at the time points
indicated, SecB+ membrane vesicles were added to the reaction
mixtures. Incubations were continued for another 15 min and then
MBP was immunoprecipitated and analyzed by NaDodSO4/PAGE
and autoradiography. The percentage of the total MBP synthesized
that was processed to mature MBP was calculated after measuring
the amount of radioactivity present as pre-MBP and mature MBP.
Background values of processing in the absence of added vesicles
were subtracted for each time point.
DISCUSSION
A component of the E. coli protein-export machinery has
been purified and shown to be biologically active by several
assays. SecB is an acidic protein with a monomer molecular
mass of -17 kDa, as determined by its migration on
NaDodSO4/PAGE. Analysis of the native protein by gel
filtration chromatography and native gel electrophoresis
indicated that SecB is probably a multimeric protein of four
to six identical subunits. SecB was absent from cells harbor-
ing a secB::TnS mutation, and fractions prepared from such
cells were markedly defective at sponsoring in vitro translo-
cation of a subset of E. coli periplasmic proteins including
MBP, thus mimicking the specific effects of the secB::Tn5
mutation on protein export in vivo (5-8). SecB appears to be
a soluble cytoplasmic protein for the following reasons: (i)
active SecB was purified from the soluble fraction of SecB-
overproducing cells; (ii) a SecB+ S-100 fraction could par-
tially complement membrane vesicles prepared from SecB-
cells for MBP translocation activity; and (iii) we had shown
(7) that S-100 fractions prepared from SecB-, SecB+, and
SecB-overproducing cells exhibited significant differences in
the rate of folding of newly synthesized pre-MBP. A SecB-
S-100 fraction also could be complemented by membrane
vesicles prepared from wild-type cells. However, since SecB
interacts with precursor proteins targeted for export, it was
not unexpected that this protein was in both the soluble and
crude membrane fractions. Furthermore, since SecB is
clearly present in haploid secB+ cells in limiting quantities
(7), the soluble and membrane fractions alone probably have
insufficient SecB to bring MBP translocation activity in such
a complementation assay up to the level obtained when both
of these fractions are prepared from SecB+ cells.
The addition of purified SecB to a SecB- S-30 fraction
significantly enhanced translocation of MBP into membrane
vesicles, but a translocation efficiency comparable to that
exhibited by SecB+ fractions was not attained. This may be
an indication that SecB was somehow altered during the
purification procedure or was purified away from some other
component required for maximal translocation activity. An-
other possibility is that SecB- cells suffer alterations in their
export machinery such that fractions prepared from these
cells exhibit a MBP translocation defect that cannot be totally
repaired by the addition of purified SecB. Providing addi-
tional SecB to a SecB+ S-30 fraction did not significantly
improve MBP translocation efficiency. Thus, a limiting
amount of available SecB probably is not responsible for the
inability to import MBP into vesicles in vitro with 100%
efficiency.
Consistent with our previous findings that SecB had an
antifolding activity that promoted MBP export (7), we found
that purified SecB added to a SecB- S-100 fraction could
significantly retard the folding ofnewly synthesized pre-MBP
into a protease-resistant form. By this assay, folding of
pre-MBP was virtually undetectable over the time course of
the experiment when 2 ,ug of SecB was added to the in vitro
reaction mixture. This effect on pre-MBP folding was iden-
tical to that obtained with an S-100 fraction prepared from
SecB-overproducing cells (7). Thus, purified SecB must still
retain the ability to specifically interact with pre-MBP in such
a manner as to significantly affect its folding kinetics. Our
earlier studies had strongly suggested that SecB binds to a
specific site within the mature moiety of the pre-MBP to
effect its antifolding activity, although at this point alternative
explanations for this antifolding activity cannot be ruled out
(7). The availability of purified biologically active SecB
should now allow us to further define the interaction between
this protein and unfolded MBP.
Randall and Hardy (9) demonstrated that folding of the
pre-MBP in the cytoplasm into a protease-resistant form
Biochemistry: Weiss et al.
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correlated with the loss in its ability to be posttranslationally
translocated. We subsequently showed that posttranslational
MBP export was particularly defective in SecB- cells and
concluded that the antifolding activity of SecB was essential
for maintaining the export competence of pre-MBP in the
cytoplasm (7). In this study, we have found that the rapid loss
in the ability of wild-type pre-MBP synthesized in vitro to be
posttranslationally imported into vesicles could be signifi-
cantly slowed by the inclusion of excess purified SecB, well
above the haploid SecB level, in the reaction mixture. The
interaction between SecB and wild-type pre-MBP in vivo is
by necessity a transient one since translocation is normally
achieved very rapidly. When translocation is prevented,
pre-MBP folding in the cytoplasm eventually occurs even in
the presence ofSecB (7, 8). However, it seems clear from our
in vitro studies that an elevated level of SecB can markedly
affect pre-MBP folding kinetics, possibly by shifting the
equilibrium of the pre-MBP-SecB interaction in favor of the
association. As an alternative to adding excess SecB, pre-
MBP competence for posttranslational import into vesicles
also could be significantly prolonged by a mutational alter-
ation in the pre-MBP that adversely affected folding (J.B.W.,
unpublished data). These findings underscore the importance
of an antifolding factor in promoting the posttranslational
translocation of MBP.
What about cotranslational MBP export which also is
defective in SecB- cells (7, 8)? Cotranslational translocation
ofMBP is not initiated until after =80%o of the nascent chain
has been synthesized (25), which includes that portion of the
pre-MBP having the SecB interaction site (7). The antifolding
activity of SecB might promote cotranslational pre-MBP
export by preventing the nascent chain from assuming a
conformation that is inhibitory to export or by keeping the
nascent chain in a conformation that ensures that the signal
peptide is readily accessible to the export machinery. On the
other hand, it has been suggested that a possible second
function of SecB is to actively facilitate the delivery of
nascent pre-MBP to the export machinery in the cytoplasmic
membrane, perhaps by directly interacting with a membrane
receptor (7, 8). It could be that the loss of this putative second
activity is primarily responsible for the defect in cotransla-
tional MBP export in SecB- cells.
In addition to SecB, other cytoplasmic protein factors from
E. coli cells that could stimulate in vitro protein translocation
activity have been identified. The 12S export factor of Muller
and Blobel (2) is -220 kDa, and the "trigger factor" de-
scribed by Crooke and Wickner (3) is -60 kDa. Weng et al.
(4) described two factors of 60 and -120 kDa. None ofthese
appear to be SecB. In addition, the isolation of temperature-
sensitive mutants defective in protein export at the nonper-
missive temperature led to the identification of SecA, a
cytoplasmic 91-kDa protein (24). The role that these various
proteins have in promoting co- and/or posttranslational
protein export has not yet been determined. Our studies
indicate that the inability to attain 100% translocation effi-
ciency of MBP in vitro is not associated with the vesicle
fraction (J.B.W., unpublished data); rather, some proportion
of the newly synthesized pre-MBP may fail to properly
interact with one or more of these other soluble factors prior
to delivery to the cytoplasmic membrane. Future use of
purified SecB and the SecB-specific antiserum should help to
define the interactions between MBP, SecB, and the various
components of the export machinery.
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